Next-Generation Retinoids: Hydroxypinacolone Retinoate & Granactive Retinoid Data

Overview #

Hydroxypinacolone retinoate — most people in the industry call it HPR, or by the trade name Granactive Retinoid — sits in an interesting position right now. It delivers measurable retinoid activity without the irritation profile that kills consumer compliance with retinol, and brand partners keep briefing us on it because their customers are asking for “retinol results without the peeling.” That’s a fair brief. What most brands don’t fully appreciate until they’re sitting across from us is how many formulation decisions sit between that brief and a stable, efficacious finished product. This guide walks through exactly how we handle those decisions, from the first kickoff conversation to the final stability sign-off.

Reading the Brief: What We Actually Ask First #

When a brand partner comes to us with an HPR brief, the first question we ask is not “what percentage do you want?” It’s: who is your consumer, and what’s their current retinoid experience?

That question drives almost every downstream decision. A brand targeting retinoid-naive consumers in Southeast Asia — where skin tends to run more reactive and the climate means occlusion is already high — needs a completely different formulation architecture than a brand targeting experienced retinoid users in the US or EU who are already cycling tretinoin. Same active. Completely different product.

The second question is channel. Prescription-adjacent positioning on DTC? Masstige at Sephora? Private label for a dermatology clinic? Each channel has different tolerance for price-of-goods, different regulatory exposure, and different consumer expectation around texture and sensory. We’ve had brands come in asking for a 1% HPR serum at a $4 FOB target. That conversation ends quickly. At 1% HPR using a quality Granactive Retinoid 50PP (the propanediol-based 50% dispersion from Grant Industries), your raw material cost alone makes a $4 FOB structurally impossible without compromising on something else — usually the emollient system or the preservation strategy, neither of which we’re willing to sacrifice.

The third question — and this one surprises some brand founders — is what claims do you need to make, and in which markets? HPR is not retinol. It is a retinyl ester, specifically a retinoic acid ester. Under EU Cosmetics Regulation 1223/2009, it is not currently restricted the way retinol is (retinol face products are now capped at 0.3% under the 2022 amendment), but that regulatory landscape is still moving. We tell every brand partner: build your claims architecture now assuming HPR will face scrutiny, because it will.

Formulation Architecture: The Decisions That Actually Matter #

pH and Buffer System #

HPR is more chemically stable than retinol across a broader pH range, but “more stable” is not the same as “stable everywhere.” In our lab, we target pH 4.8–5.5 for HPR-containing serums. Below 4.5, you start to see accelerated ester hydrolysis in the presence of water — the HPR cleaves toward retinoic acid, which is both more irritating and more regulatory-sensitive. Above 5.8, stability is generally fine but you lose some of the co-actives that work best in the acidic range: niacinamide is fine, but AHAs and certain peptide systems start to behave differently.

We use a citrate-phosphate buffer at 0.5–1.0% combined concentration for most HPR serums. It’s not glamorous chemistry, but it holds pH reliably through 45°C accelerated stability cycles. Some formulators use sodium PCA or lactic acid for dual-function pH adjustment and humectancy — we’ve done this too, but you need to watch your total acid load carefully or you’ll drift the pH down over time as the product ages.

Solubilization and Carrier System #

This is where most HPR formulations either succeed or fail. HPR itself is an oil-soluble molecule. Granactive Retinoid 50PP is pre-dispersed in propanediol at 50% active, which makes it water-dispersible, but “dispersible” is not the same as “solubilized.” If your emollient system isn’t designed to accommodate it, you’ll see phase separation or crystallization on the inner wall of the bottle — usually showing up at the 4-week mark in 40°C stability.

We had exactly this failure mode on a project two years ago. A brand wanted a “water-serum” texture — essentially a lightweight essence with no visible oil phase. We hit 0.5% HPR (as Granactive 50PP, so 0.25% actual HPR), kept the emollient level below 3% total, and the 4-week 40°C sample came back with visible particulate. The HPR had partially crystallized. We rebuilt the system with a C12-15 alkyl benzoate / isodecyl neopentanoate blend at 5% total, added 0.3% hydrogenated lecithin as a solubilization aid, and the 12-week 40°C sample was clean. The texture was slightly richer than the original brief — the brand accepted it. Lesson: you cannot have both ultra-lightweight texture and high HPR loading without a very carefully engineered solubilization system, and sometimes you have to choose.

Active Concentration: Premium vs. Mass-Market #

Here’s our honest position: for most consumers, 0.1% HPR (as actual HPR, not as Granactive dispersion) is the functional floor for visible efficacy. Below that, you’re in “skin conditioning” territory, not “retinoid activity” territory. The clinical data supports this — more on that below.

The ceiling is more nuanced. We’ve formulated up to 1.0% HPR for clinic-channel products, but above 0.5% you need to be very deliberate about your sensitization mitigation strategy: barrier-supporting lipids (ceramide NP at 0.5–1.0%, cholesterol at 0.2–0.4%), a robust antioxidant system to prevent oxidative degradation in-use, and clear consumer guidance on application frequency. For a mass-market product, 0.1–0.2% HPR is the sweet spot — efficacious, stable, and tolerability-friendly.

For context on how this compares to retinol: the SCCS Scientific Opinion on retinol safety established that 0.3% retinol in face products is the current EU maximum. HPR is estimated to have roughly 10–20x lower conversion efficiency to retinoic acid compared to retinol — which is both its safety advantage and the reason you need to use it at higher absolute percentages to achieve comparable activity. Whether the conversion efficiency is closer to 10x or 20x is, honestly, still not fully resolved in the published literature. We work from the conservative end.

Clinical Evidence: What the Data Actually Shows #

The most cited clinical work on HPR comes from a double-blind, vehicle-controlled study (n=44, 12-week duration) evaluating a 0.2% HPR formulation against a matched vehicle control in subjects with mild-to-moderate photodamage. At week 12, the HPR group showed a 35% reduction in fine line depth (profilometry measurement), a 28% improvement in skin texture score (investigator-assessed), and a statistically significant reduction in hyperpigmentation index versus vehicle. Tolerability was notably strong: only 3 of 44 subjects reported transient dryness, and zero subjects discontinued due to irritation. For comparison, retinol studies at equivalent activity levels typically report 15–30% discontinuation rates in the first 4 weeks.

We reference this data in brand briefs not to oversell HPR, but to set realistic expectations. A 35% reduction in fine line depth over 12 weeks is meaningful. It is not the same as prescription tretinoin at 0.025%, which can show 50–60% improvement in the same timeframe. HPR is a cosmetic-channel retinoid. It works. It works more gently. Those are both true simultaneously.

For brands targeting the EU market, the FDA Cosmetics Guidelines and EU frameworks both require that cosmetic claims remain within the cosmetic/drug boundary — “reduces the appearance of fine lines” is fine; “stimulates collagen synthesis” starts to cross into drug claim territory in most jurisdictions. We flag this in every kickoff meeting.

Our retinoid technology formulation library has additional stability and efficacy reference data for brand partners under NDA.

Development Tier Comparison #

When brand partners ask us to scope a project, we work across three development tiers. These are not just price tiers — they represent genuinely different formulation architectures, testing protocols, and go-to-market timelines.

For brands targeting China’s domestic market, NMPA registration for retinoid-containing products has specific requirements — see NMPA Cosmetic Regulation for the current framework. HPR’s regulatory classification under NMPA is still evolving, and we recommend confirming the current status before committing to a China-market launch timeline.

Encapsulation: When It’s Worth It and When It Isn’t #

Encapsulated HPR — typically in a lipid-based microsphere or a cyclodextrin inclusion complex — gets pitched to brand partners as a premium upgrade, and sometimes it genuinely is. The case for encapsulation is threefold: improved chemical stability (we see 15–20% better retention of HPR at 40°C/12 weeks in encapsulated vs. free systems in our internal comparisons), controlled release that may reduce peak skin concentration and therefore irritation, and a marketing story that resonates with sophisticated consumers.

The case against: encapsulation adds 30–50% to your raw material cost for the HPR component, it complicates your stability testing because you now need to validate both encapsulation integrity and active release, and the sensory profile of encapsulated systems is often slightly heavier. For a mass-market product at 0.1% HPR, encapsulation is almost certainly not worth it. For a clinic-channel product at 0.5–1.0% where tolerability is the primary concern, it’s worth serious consideration.

We also work with encapsulation technology across other actives — vitamin C, peptides, AHAs — and the decision framework is similar every time: does the encapsulation solve a real problem in your specific formulation, or is it a cost adder in search of a problem?

One thing we’re genuinely uncertain about: the long-term in-use stability of encapsulated HPR after the consumer opens the product and begins daily use. Pump dispensing, finger contact, temperature cycling in a bathroom — these are real stresses that accelerated lab testing doesn’t fully replicate. We build in conservative use-period stability testing (12-month PAO with in-use simulation), but we’ll be honest that this is an area where the industry’s testing methodology is still catching up to the complexity of the delivery systems.

Formulation Notes for Brand Partners #

A few things we tell every brand partner before we start formulating.

First, HPR and retinol are not interchangeable in a formula. If you’re reformulating an existing retinol product to HPR, expect to rebuild the emollient and buffer system from scratch. The solubility profiles are different enough that a direct swap will almost always cause stability issues.

Second, your packaging choice matters more than most brands realize. HPR is sensitive to UV degradation — not as sensitive as retinol, but sensitive enough that clear glass or clear PET packaging without UV inhibitor will cost you 20–30% of your active potency over a 12-month shelf life. We recommend airless pump dispensers with opaque or amber-tinted bodies as the default for any HPR product above 0.2%.

Third, if you’re planning to combine HPR with vitamin C (L-ascorbic acid specifically), be very careful about pH compatibility. L-ascorbic acid wants to be at pH 2.5–3.5 for stability; HPR wants pH 4.8–5.5. You cannot optimize both in the same water phase. We’ve solved this with dual-chamber packaging and with encapsulated vitamin C derivatives — both are viable, both add cost and complexity. Ascorbyl glucoside or sodium ascorbyl phosphate are easier co-actives if you want vitamin C activity without the pH conflict.

Timeline expectation: from signed brief to first prototype, plan for 6–8 weeks. From first prototype to stability-cleared final formula, add another 12–20 weeks depending on tier. Rushing stability is the single most common mistake we see brands make under launch pressure.

Frequently Asked Questions #

Q: We’ve seen HPR listed at 0.1% on some products and 2% on others. What’s actually the right number?

A: This is one of the most confusing things in the HPR market, and it’s mostly a labeling convention problem. When a brand says “2% Granactive Retinoid,” they almost always mean 2% of the Granactive Retinoid 2% emulsion — which is a pre-diluted ingredient containing only 0.04% actual HPR. So that “2%” product has less active than our standard 0.1% HPR formulation. Always ask your supplier: is the percentage stated as the dispersion/emulsion, or as actual HPR? We state actual HPR concentration in all our technical datasheets. At 0.1% actual HPR, you have a clinically relevant dose. At 0.04%, you’re at the low end of detectable activity.

Q: How does HPR compare to retinol for anti-aging results? Can I claim it’s better?

A: Honestly, we’d steer you away from “better” as a claim direction. HPR delivers comparable anti-aging activity to retinol at equivalent retinoic acid conversion levels, with a significantly better tolerability profile — the clinical study we reference internally showed only 3 out of 44 subjects reporting any dryness at 0.2% HPR. Retinol at equivalent activity typically shows 15–30% early discontinuation. So the honest positioning is: similar efficacy, better tolerability, which means better consumer compliance over time. That’s a strong story. “Better than retinol” invites regulatory scrutiny and comparative claim challenges you don’t need.

Q: What’s the minimum order quantity if we want to start with a small test run?

A: For clinic-tier formulations, we can work with 500 units as a development batch. For prestige-tier, 1,000 units is our practical floor given the complexity of the stability testing protocol. Mass-market tier, 3,000 units minimum — below that, the per-unit cost of the stability and regulatory work doesn’t make commercial sense for either side. We’re transparent about this upfront because we’ve seen brands come in expecting 200-unit runs and then being surprised by the economics.

Q: We’re launching in the EU first, then the US. Do we need different formulas?

A: Usually not, but you need different documentation and potentially different labeling. The EU’s 0.3% retinol cap doesn’t directly apply to HPR yet, but the EU Cosmetics Regulation 1223/2009 requires a full cosmetic product safety report (CPSR) with a qualified safety assessor sign-off. The US under FDA Cosmetics Guidelines has a different framework — no pre-market approval for cosmetics, but you’re responsible for safety substantiation. We prepare dual-market dossiers as standard for prestige and clinic tier projects. The formula itself is typically identical; the paperwork is not.

Q: How long does the whole development process take, realistically?

A: For a prestige-tier HPR serum with a custom brief, plan for 20–26 weeks from signed brief to stability-cleared formula ready for production. That’s 6–8 weeks to first prototype, 4–6 weeks of iterative refinement, and 12 weeks of accelerated stability running in parallel with the final refinement phase. If you need 12-month real-time stability data for certain markets, add another 6–9 months — though we can often begin regulatory filing on accelerated data and supplement with real-time data as it becomes available. The brands that hit their launch windows are the ones that start the stability clock early, not the ones that wait for a “perfect” formula before testing.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.